Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Smoking and Risk of Vision Threatening Complications: A Global Database Analysis.
Journal: Clinical ophthalmology (Auckland, N.Z.)
Published: February 06, 2026
Synthesis of 3-Aminobenzisoxazoles Using an Electrophilic Aminating Reagent.
Journal: Organic letters
Published: January 09, 2026
Comprehensive proteolytic profiling of Aedes aegypti mosquito midgut extracts: Unraveling the blood meal protein digestion system.
Journal: PLoS neglected tropical diseases
Published: September 22, 2024
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.
Journal: Journal of medicinal chemistry
Published: June 10, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.
Journal: Cancer cell
Published: November 02, 2020
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
Journal: The Journal of biological chemistry
Published: October 28, 2020
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Journal: Journal of medicinal chemistry
Published: March 14, 2017
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Journal: Journal of medicinal chemistry
Published: January 13, 2016
Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).
Journal: Journal of medicinal chemistry
Published: November 02, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026